As we’ve learned more about Parkinson’s, we’ve found that it shares some of the same underlying molecular pathways and mechanisms as other diseases. For example, there is overlap with diabetes as well as some inflammatory disorders. Investigating drugs that were originally designed to treat these other diseases and that act on these shared pathways provides a particularly promising avenue for more quickly and more effectively finding treatments that slow or stop Parkinson’s. The Linked Clinical Trials initiative is the largest such effort of its kind for Parkinson's, and the work it supports is generating a wealth of data that will go a long way toward finding a game-changing treatment. 

Professor Patrik Brundin, Chair, The Linked Clinical Trials (LCT) Committee

In a recently published paper, the safety and potential efficacy of the most promising candidates being repurposed as potential disease-modifying treatments for Parkinson’s in the advanced stages of clinical testing, are presented and discussed.

This informative paper by Dr Dilan Athauda and Professor Tom Foltynie provides an independent rationale and context for The Cure Parkinson's Trust (CPT) and Van Andel Research Institute's LCT programme and features a number of the LCT candidate drugs currently being brought to trial. 

The LCT initiative was launched in 2012. Since then, the committee has prioritised over 30 therapies that have the potential to slow, stop or even reverse Parkinson's.

This massive clinical undertaking involving so many drugs repurposed from other therapeutic areas is unique not only in neurology, but is larger than any drug development programme, whether academic or commercial, in any other disease

Dr Richard Wyse, Director of Research & Development, CPT

Find out more about our LCT drugs in trials now and those drugs recently selected by the LCT committee awaiting trial in Parkinson's.